EU Clears Baxter's $4B Gambro Buy With Conditions

Law360, New York (July 22, 2013, 4:05 PM EDT) -- The European Commission on Monday cleared Baxter International Inc.'s $4 billion bid for Swedish dialysis product maker Gambro AB on the condition that Baxter sell off its unit that offers acute kidney failure treatments.

The European Union's antitrust watchdog said without the divestiture, the transaction would have given Baxter too strong a hold over the market for continuous renal replacement therapy in a significant chunk of the bloc's 27 members. But as long as the Illinois-based medical company sheds its CRRT unit, the deal will not...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.